Osimertinib

ArtNr	HY-15772-500mg
Hersteller	MedChem Express
CAS-Nr.	1421373-65-0
Menge	500 mg
Quantity options	100 mg 10 mM/1 mL 10 mg 1 g 1 mg 200 mg 500 mg 50 mg 5 mg
Kategorie	Oncology Neuroscience Neural Signaling Inhibitors & Compound Libraries Small Molecules By Organ Bladder Cancer Colorectal Cancer
Typ	Inhibitors
Specific against	other
Purity	99.99
Citations	[1]Cross DA, et al. AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer. Cancer Discov. 2014 Sep;4(9):1046-61.\|[2]Hirano T, et al. Pharmacological and Structural Characterizations of Naquotinib, a Novel Third-Generation EGFR Tyrosine Kinase Inhibitor, in EGFR-Mutated Non-Small Cell Lung Cancer. Mol Cancer Ther. 2018 Apr;17(4):740-750. ACS Nano. 2022 Jul 21.\|Acta Pharmacol Sin. 2019 Dec;40(12):1587-1595. \|Acta Pharmacol Sin. 2021 Jan 7.\|Acta Pharmacol Sin. 2021 Jan;42(1):108-114.\|Acta Pharmacol Sin. 2024 Dec 3.\|Adv Sci (Weinh). 2024 Dec 16:e2411479.\|Adv Sci (Weinh). 2024 May 2:e2306348.\|Adv Ther. 2024 Jul 18.\|Am J Cancer Res. 2023 Sep 15;13(9):4145-4162.\|Am J Transl Res. 2021 Jun 15;13(6):6055-6065.\|Anticancer Res. 2024 Oct;44(10):4175-4188.\|Anticancer Res. 2019 Sep;39(9):4817-4828.\|Appl Surf Sci. 2024 Dec 21.\|Biochem Biophys Res Commun. 2024 Sep 19:733:150711.\|Biol Methods Protoc. 2025 Feb 13.\|Biomed Pharmacother. 2024 Jan 9:171:116124.\|Bioorg Chem. 2023 Mar 27.\|bioRxiv. 2023 Oct 27.\|bioRxiv. 2024 Feb 12.\|bioRxiv. 2025 January 21.\|Cancer Cell Int. 2021 Apr 15;21(1):216.\|Cancer Cell Int. 2021 Jul 3;21(1):337.\|Cancer Discov. 2019 Jul;9(7):926-943.\|Cancer Gene Ther. 2022 Sep 19.\|Cancer Res Treat. 2023 Jan 26.\|Cancer Res. 2023 Apr 16;CAN-22-3059.\|Cancer Res. 2023 Dec 14.\|Cancer Res. 2023 May 2;83(9):1490-1502.\|Cancer Res. 2025 Feb 1;85(3):585-601.\|Cancers. 2019 Jul 5;11(7):947.\|Cancers. 2019 Oct 14;11(10):1550.\|Cell Chem Biol. 2018 Aug 16;25(8):996-1005.e4.\|Cell Death Differ. 2024 May 30.\|Cell Death Dis. 2019 Aug 13;10(8):615.\|Cell Death Dis. 2019 May 1;10(5):361. \|Cell Oncol. 2022 Sep 21.\|Cell Rep Med. 2023 Jan 10;100911.\|Cell Rep Med. 2024 Mar 19;5(3):101471.\|Cell Rep. 2024 Oct 8;43(10):114812.\|Commun Biol. 2021 Dec 13;4(1):1391.\|Cytotechnology. 2025 Feb;77(1):23.\|Drug Deliv Transl Res. 2021 Nov 23.\|Drug Metab Pharmacokinet. 2020 Oct;35(5):456-465.\|Environ Toxicol. 2019 Apr;34(4):476-485. \|Eur J Drug Metab Pharmacokinet. 2021 Jul 18;1-11.\|Eur J Pharmacol. 2021, 174297.\|Exp Hematol Oncol. 2024 Oct 1;13(1):97.\|Faculty of Medicine. University of Oslo. 2019 Feb.\|Fundam Clin Pharmacol. 2021 Feb 1.\|Genes (Basel). 2024 Dec 19;15(12):1624.\|Genes Cancer. 2017 Mar;8(3-4):497-504.\|Genes Genomics. 2024 Dec 20.\|Int Immunopharmacol. 2023 Nov 23:126:111265.\|Int J Anal Chem. 2020 Dec 29.\|Int J Biol Macromol. 2024 May;268(Pt 1):131560.\|Int J Biol Sci. 2021; 17(7):1671-1681.\|Int J Mol Med. 2023 Nov;52(5):102.\|Int J Mol Sci. 2023 May 15, 24(10), 8794.\|Int J Oncol. 2020 Jan;56(1):243-257.\|J Biol Chem. 2023 May 11;104814.\|J Cell Physiol. 2021 Nov 21.\|J Chromatogr B Analyt Technol Biomed Life Sci. 2024 Mar 26:1237:124100.\|J Control Release. 2024 Nov 5:376:829-841.\|J Ethnopharmacol. 2024 Jul 18:118586.\|J Exp Clin Cancer Res. 2019 Mar 15;38(1):129.\|J Exp Clin Cancer Res. 2025 Mar 11;44(1):95.\|J Exp Clin Cancer Res. 2019 Mar 15;38(1):129. \|J Exp Clin Cancer Res. 2019 May 23;38(1):219. \|J Med Chem. 2017 Apr 13;60(7):2944-2962. \|J Med Chem. 2023 Apr 11.\|J Nat Med. 2023 Apr 12.\|J Natl Cancer Inst. 2023 Jul 22;djad142.\|J Pharm Anal. 2021 Jun 19.\|Mol Cancer Res. 2019 Feb;17(2):499-507. \|Mol Cancer Res. 2019 Nov;17(11):2233-2243.\|Mol Cancer Res. 2024 Jul 2.\|Mol Cancer Ther. 2018 Mar;17(3):603-613.\|Mol Cancer Ther. 2019 May;18(5):920-928.\|Mol Cancer Ther. 2023 Sep 5;22(9):1013-1027.\|Mol Med Rep. 2021 Jan;23(1):48.\|Mol Oncol. 2023 Apr 4.\|Mol Pharmacol. April 5, 2022.\|Nat Cancer. 2022 Apr;3(4):402-417.\|Nat Cancer. 2023 Jun;4(6):829-843.\|Neoplasia. 2024 Aug 14:57:101039.\|Oncogene. 2022 May;41(22):3104-3117.\|Oncogene. 2024 Aug 15.\|Oncogene. 2024 Oct 14.\|Oncogene. 2025 Feb 26.\|Oncol Lett. 2023 Jul 20.\|Oncotarget. 2015 Oct 13;6(31):31313-22. \|Oncotarget. 2016 Oct 25;7(43):69760-69769.\|Oncotarget. 2017 Mar 14;8(11):18359-18372. \|Patent. US20190010159A1.\|Patent. US20200276189A1.\|Patent. US20210315911A1.\|Patent. US20230158019A1.\|Pharmaceutics. 2024 Nov 12;16(11):1444.\|PLoS One. 2024 Nov 1;19(11):e0308647.\|Research Square Preprint. 2021 Jul.\|Research Square Preprint. 2021 Jun.\|Research Square Preprint. 2021 Mar.\|Research Square Preprint. 2021 May.\|Research Square Preprint. 2023 May 5.\|Research Square Preprint. 2024 Dec 02.\|Research Square Preprint. 2024 Jan 3.\|Research Square Preprint. 2024 Nov 26.\|Research Square Print. December 21st, 2022.\|Respir Physiol Neurobiol. 2020 Oct;281:103496.\|Respir Res. 2024 May 20;25(1):215.\|RSC Chem Biol. 2023 Aug 29.\|Theranostics. 2021 Jan 19;11(7):3392-3416.\|Theranostics. 2021 Mar 24;11(12):5650-5674.\|Transl Lung Cancer Res. 2024 Oct 31;13(10):2698-2712.\|Universitat Politècnica de València. 2021 Sep.\|Cancer Cell. 2020 Jan 13;37(1):104-122.e12.\|Cancer Lett. 2023 May 19;216237.\|Commun Biol. 2024 Mar 1;7(1):250.\|Int J Electrochem Sci. 2024 Nov 26.\|Oncotarget. 2017 Dec 6;9(2):1641-1655.\|Research Square Preprint. 2023 Jun 30.\|Xenobiotica. 2018 Nov;48(11):1106-1112.\|Research Square Preprint. 2021 May.
Smiles	C=CC(NC1=CC(NC2=NC=CC(C3=CN(C)C4=C3C=CC=C4)=N2)=C(OC)C=C1N(CCN(C)C)C)=O
ECLASS 10.1	32160490
ECLASS 11.0	32160490
UNSPSC	12000000
Alias	AZD-9291,Mereletinib
Versandbedingung	Raumtemperatur
Lieferbar
Manufacturer - Type	Reference compound
Manufacturer - Applications	Cancer-Kinase/protease
Manufacturer - Targets	EGFR
Shipping Temperature	Room Temperature
Storage Conditions	-20°C, 3 years; 4°C, 2 years (Powder)
Molecular Weight	499.61
Product Description	Osimertinib (AZD9291) is a covalent, orally active, irreversible, and mutant-selective EGFR inhibitor with an apparent IC50 of 12 nM against L858R and 1 nM against L858R/T790M, respectively. Osimertinib overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer[1].
Manufacturer - Research Area	Cancer
Solubility	DMSO: 100 mg/mL (ultrasonic)
Manufacturer - Pathway	JAK/STAT Signaling; Protein Tyrosine Kinase/RTK
Isoform	EGFR/ErbB1/HER1
Clinical information	Launched

Hinweis: Die dargestellten Informationen und Dokumente (Bedienungsanleitung, Produktdatenblatt, Sicherheitsdatenblatt und Analysezertifikat) entsprechen unserem letzten Update und sollten lediglich der Orientierung dienen. Wir übernehmen keine Garantie für die Aktualität. Für spezifische Anforderungen bitten wir Sie, uns eine Anfrage zu stellen.

Alle Produkte sind nur für Forschungszwecke bestimmt. Nicht für den menschlichen, tierärztlichen oder therapeutischen Gebrauch.

Arbeitsanleitung (Data Sheet) anfordern

Produkt-Datenblatt anfordern

HY-15772-500mg-safety-datasheet.pdf